News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
685,662 Results
Type
Article (39056)
Company Profile (279)
Press Release (646327)
Section
Business (203870)
Career Advice (1991)
Deals (35364)
Drug Delivery (85)
Drug Development (80801)
Employer Resources (168)
FDA (16088)
Job Trends (14805)
News (344555)
Policy (32439)
Tag
Academia (2530)
Alliances (49088)
Alzheimer's disease (1229)
Approvals (16020)
Artificial intelligence (130)
Bankruptcy (352)
Best Places to Work (11538)
Biotechnology (200)
Breast cancer (120)
Cancer (1087)
Cardiovascular disease (97)
Career advice (1660)
Cell therapy (234)
Clinical research (64253)
Collaboration (388)
Compensation (200)
COVID-19 (2530)
C-suite (94)
Data (1126)
Diabetes (152)
Diagnostics (6139)
Earnings (84822)
Employer resources (146)
Events (109490)
Executive appointments (310)
FDA (16627)
Funding (353)
Gene therapy (178)
GLP-1 (577)
Government (4325)
Healthcare (18669)
Infectious disease (2615)
Inflammatory bowel disease (106)
Interviews (308)
IPO (16303)
Job creations (3624)
Job search strategy (1417)
Layoffs (412)
Legal (7853)
Lung cancer (170)
Manufacturing (176)
Medical device (13175)
Medtech (13180)
Mergers & acquisitions (19142)
Metabolic disorders (402)
Neuroscience (1504)
NextGen Class of 2024 (6499)
Non-profit (4464)
Northern California (1481)
Obesity (232)
Opinion (179)
Patents (102)
People (56276)
Phase I (19955)
Phase II (28304)
Phase III (21099)
Pipeline (458)
Postmarket research (2554)
Preclinical (8494)
Radiopharmaceuticals (236)
Rare diseases (219)
Real estate (5890)
Regulatory (21527)
Research institute (2309)
Resumes & cover letters (349)
Southern California (1302)
Startups (3562)
United States (13500)
Vaccines (549)
Weight loss (168)
Date
Today (1)
Last 7 days (667)
Last 30 days (3542)
Last 365 days (35660)
2024 (32755)
2023 (40074)
2022 (51173)
2021 (55712)
2020 (54090)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29264)
2010 (27329)
Location
Africa (713)
Arizona (192)
Asia (37123)
Australia (6059)
California (3331)
Canada (1295)
China (252)
Colorado (147)
Connecticut (153)
Europe (79514)
Florida (461)
Georgia (116)
Illinois (341)
Indiana (196)
Kansas (96)
Maryland (575)
Massachusetts (2611)
Michigan (158)
Minnesota (273)
New Jersey (957)
New York (964)
North Carolina (702)
Northern California (1481)
Ohio (139)
Pennsylvania (847)
South America (1091)
Southern California (1302)
Texas (465)
Utah (90)
Washington State (362)
685,662 Results for "gtx inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
Ultragenyx Pharmaceutical Inc. announced new data from the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome.
April 15, 2024
·
12 min read
Press Releases
Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024
October 30, 2024
·
10 min read
Press Releases
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
November 11, 2024
·
8 min read
Business
Halberd Corp. Signs Significant Revenue Sharing Agreement with Athena GTX
Halberd Corporation is thrilled to declare the formalization of a profitable revenue-sharing accord with Athena GTX, Inc., of Johnston, Iowa,. Athena GTX is a private enterprise specializing in providing medical care solutions tailored for first responders in both civilian and government sectors.
January 9, 2024
·
5 min read
Biotech Bay
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the conference call to discuss new clinical efficacy and safety data from the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome that will be presented at the American Academy of Neurology Meeting (AAN), will now be taking place on Monday, April 15, 2024 at 8 a.m. Eastern Time (ET).
April 12, 2024
·
1 min read
Biotech Bay
Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to GTX-102 for the treatment of Angelman syndrome (AS).
February 5, 2024
·
7 min read
Press Releases
Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104
September 26, 2024
·
7 min read
Drug Development
Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome
Ultragenyx Pharmaceutical Inc. today announced the completion of patient enrollment in its Phase 1/2 clinical trial of GTX-102 for the treatment of pediatric patients with Angelman syndrome (AS).
January 3, 2024
·
6 min read
Press Releases
Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
July 24, 2024
·
7 min read
Press Releases
Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
July 18, 2024
·
8 min read
1 of 68,567
Next
